Document Detail

Urinary placental growth factor differentiates the hypertensive disorders of pregnancy.
MedLine Citation:
PMID:  21883135     Owner:  NLM     Status:  Publisher    
Aims:  To evaluate the discriminating capacity of urinary placental growth factor (uPlGF) for different hypertensive diseases of pregnancy during the third trimester. Methods:  A prospective descriptive case-control study conducted in an urban tertiary referral hospital and district general hospital, Sydney South West Area Health Service, Australia. Inpatients and outpatients with and without hypertension in the third trimester were recruited. Eligible patients provided a urine sample for protein, creatinine and a uPlGF level by ELISA. Patients were categorised into clinical hypertensive groups based on the diagnostic criteria of SOMANZ. Results:  Eighty-eight women were evaluated; 41 had hypertension (15 pre-eclampsia; 13 gestational hypertension; eight chronic hypertension; five pre-eclampsia superimposed on chronic hypertension) and 47 women without hypertension as the control group. There was a significant difference in uPlGF levels between the pre-eclamptic group (median 2.56 IQR 1.12-4.51) and the normotensive controls (median 13.18 IQR 5.95-31.39) (P < 0.0001); the gestational hypertensive group (median 3.74 IQR 2.49-4.91) and the normotensive group (median 13.18 IQR 5.95-31.39) (P = 0.002) and for a subgroup comparison of placental-mediated hypertension (median 2.75 IQR 1.38-4.82) versus non-placental-mediated hypertensives (median 6.96 IQR 3.87-12.54) (P = 0.007). Conclusions:  Urinary placental growth factor is a simple non-invasive test, which is discriminatory for pre-eclampsia in the third trimester of pregnancy. Results from this study indicate that it may be discriminatory for hypertension related to placental dysfunction (pre-eclampsia and gestational hypertension) when compared with hypertension unrelated to placental function. Further work is required to assess the ability to detect hypertensive diseases before they are clinically apparent.
Neil Campbell; Robert Ogle; Charlene Thornton; Annemarie Hennessy; Jason Abbott
Related Documents :
22042285 - In utero diagnosis and management of a fetus with homozygous α-thalassemia in the seco...
1581275 - A randomized controlled trial to compare three types of fetal scalp electrode.
21922045 - Use of continuous electronic fetal monitoring in a preterm fetus: clinical dilemmas and...
14609615 - Postural position and neurocardiogenic syncope in late pregnancy.
7816395 - Reproductive toxicology of alkylating agents.
9653695 - Creighton model naproeducation technology for avoiding pregnancy. use effectiveness.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-8-22
Journal Detail:
Title:  The Australian & New Zealand journal of obstetrics & gynaecology     Volume:  -     ISSN:  1479-828X     ISO Abbreviation:  -     Publication Date:  2011 Aug 
Date Detail:
Created Date:  2011-9-2     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0001027     Medline TA:  Aust N Z J Obstet Gynaecol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Copyright Information:
© 2011 The Authors. Australian and New Zealand Journal of Obstetrics and Gynaecology © 2011 The Royal Australian and New Zealand College of Obstetricians and Gynaecologists.
Royal Hospital for Women and University of New South Wales Royal Prince Alfred Hospital - Women and Babies University of Western Sydney, School of Medicine, New South Wales, Australia.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Diagnosis and treatment of hypertension 21?years after a hypertensive disorder of pregnancy.
Next Document:  Lack of evidence for a protective effect of prolonged breastfeeding on childhood eczema: lessons fro...